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Background/aim: Increased neuropathic pain (NP) symptoms are seen in rheumatologic diseases such as fibromyalgia, osteoarthritis,
and rheumatoid arthritis, but no studies have demonstrated a relationship between ankylosing spondylitis (AS) and NP except for a
brain imaging study. The aim of this study was to estimate the presence of NP in patients with AS and to investigate how NP was related
to disease activity, functional status, and quality of life.
Materials and methods: A total of 100 AS patients (71 males and 29 females; median age: 37 years, range: 18–71 years) were included in
the study. Pain (visual analog scale (VAS) and the painDETECT questionnaire), disease activity (Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), Patient Global Assessment of Disease Activity
(PGA), and Ankylosing Spondylitis Disease Activity Score (ASDAS)), functional level (Bath Ankylosing Spondylitis Functional Index
(BASFI)), and health-related quality of life (36-Item Short Form Survey (SF-36)) were evaluated. Patients were divided into two groups.
Group 1 included patients with possible or likely NP symptoms (painDETECT score of ≥13) and Group 2 included patients without NP
symptoms (painDETECT score of <13).
Results: Low back pain-VAS, peripheral joint-VAS, BASDAI, PGA, ASDAS, and BASFI scores were significantly higher in Group 1
compared to those of Group 2 (P < 0.05). The SF-36 physical component (PC) score was significantly lower in Group 1 compared to
that of Group 2 (P < 0.05). There were no significant differences between the groups regarding SF-36 mental component (MC) scores,
erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) values and MASES scores. Total painDETECT scores correlated
positively with low back pain-VAS, peripheral joint-VAS, morning stiffness-VAS, BASDAI, ASDAS-CRP, ASDAS-ESR, PGA, BASFI,
and MASES scores and ESR values, and inversely with SF-36 PC scores.
Conclusion: Our results suggest that AS patients should be evaluated in terms of NP in order not to underestimate NP. If clinicians find
evidence of likely NP, they should treat the patient with drugs that target NP.
Key words: Neuropathic pain, ankylosing spondylitis

1. Introduction
Ankylosing spondylitis (AS) is a rheumatic disease
characterized by chronic inflammatory back pain due to
sacroiliac joint and spine involvement. Peripheral joints
and extraarticular findings should also be seen (1). It
is now known that mixed pain patterns may develop in
chronic diseases by the addition of a neuropathic pain
(NP) component to existing pain mechanisms (2,3).
NP is caused by a lesion or disease affecting the
somatosensory nervous system (4). It is maladaptive and
continues even when the stimulus disappears (5). Burning,
stinging pain is typically described. Abnormal sensations
such as allodynia or hyperalgesia may be observed. The
presence of symptoms of NP has been shown in rheumatic
* Correspondence: drgul_can@hotmail.com

diseases such as fibromyalgia (6,7), osteoarthritis (8,9),
and rheumatoid arthritis (10,11).
There is only one recent study that indicated the
presence of NP in AS (12). In that study, correlations of
painDETECT scores and abnormal brain gray matter
findings were shown. However, so far the relationship
between NP and disease activity, functional status, quality
of life, and demographic characteristics have not been
investigated in AS.
AS differs from other rheumatic diseases such as
rheumatoid arthritis as acute-phase reactants such as
erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) values are not highly correlated with disease
activity (13). Disease activity is evaluated with subjective
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methods in AS. The Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) is the most widely used scale
to determine disease activity in AS (14). The BASDAI
has an important role in deciding treatment and followup. However, it is a subjective assessment consisting of
questions about neck, hip, and back pain; peripheral
joint pain; stiffness; fatigue; and tenderness on pressure
and palpation (14). This index may be affected by
accompanying NP symptoms. The NP symptoms cannot
be treated with traditional antiinflammatory or diseasemodifying drugs or biological agents. High disease activity
and low functional level despite treatment in patients with
AS may be due to the NP component.
The painDETECT questionnaire is the most widely
used and accepted quantitative tool in the diagnosis of
NP (15). It has been used in the diagnosis of NP in many
musculoskeletal disorders such as fibromyalgia, low back
pain, osteoarthritis, and rheumatoid arthritis (10,11,16–
18). To date, use of the painDETECT questionnaire has
not been reported widely in assessments of people with
AS.
We aimed to investigate the presence of NP in patients
with AS using the painDETECT questionnaire and to
investigate the relationship between NP and disease
activity, functional status, and quality of life.
2. Materials and methods
We conducted a study of 100 participants (71 males and
29 females) with AS diagnosed based on the modified
New York criteria (19) from the Rheumatologic
Diseases Outpatient Clinic of the Physical Medicine and
Rehabilitation Department. Demographic data including
age, sex, education level, current tobacco or alcohol use,
current treatment, use of nonsteroid antiinﬂammatory
drugs (NSAIDs) or disease-modifying antirheumatic
drugs (DMARDs), and biological therapies were also
recorded. Ethical approval for this study was provided by
the local ethics committee. All patients provided written
informed consent.
Participants were interviewed during routine clinic
appointments and identified from clinic records. They
were eligible to participate in the study if their treatment
had been stable for the previous 3 months. Patients who
had neuropsychiatric conditions (e.g., radiculopathy,
polyneuropathy, neuropathy, depression, fibromyalgia)
and/or musculoskeletal disorders (e.g., surgery, fracture)
and/or endocrine diseases (e.g., diabetes mellitus) and/
or malignancy were excluded based on their history and
clinical examination.
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2.1. Measures
2.1.1. Pain assessment tools
2.1.1.1. Visual analog scale (VAS) (0–10)
The VAS was used to record each patient’s current level of
low back pain and peripheral joint pain, with 0 indicating
no pain and 10 indicating the worst pain that the patient
had ever experienced. Using a ruler marked in centimeters,
the examiner obtained the exact values along a 10-cm VAS
line.
2.1.1.2. Morning stiffness
The patient’s current duration of morning stiffness was
recorded, with 0 indicating no stiffness and 10 indicating
stiffness lasting ≥2 h.
2.1.1.3. painDETECT questionnaire
NP symptoms were assessed using the Turkish version of
the painDETECT questionnaire (20). It consists of seven
items evaluating pain qualities, one evaluating the course
of pain, and one evaluating pain radiation. Additionally,
the questionnaire contains three numerical rating scales
(NRSs) of 0–10 for current, worst, and average pain
severity. An overall score is generated that summarizes
everything but the pain intensity NRS, which ranges
between –1 and 38. An overall score of >18 indicates likely
NP, 13–18 possible NP, and <13 unlikely NP. The Turkish
validation of the painDETECT questionnaire was reported
by Alkan et al. (20).
2.1.2. Assessment of disease activity
2.1.2.1. Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI)
The BASDAI has six NRSs of 0–10 to measure the severity
of fatigue, spinal and peripheral joint pain, localized
tenderness, and morning stiffness in patients with AS.
The final BASDAI score has a range of 0–10, with lower
numbers representing less severe disease activity (14). A
score of 4 has been determined as the BASDAI cut-off value
for assessment of disease activity; that is, BASDAI values
of greater than 4 indicate the presence of active disease.
The Turkish validation of the BASDAI was reported by
Akkoc et al. (21).
2.1.2.2. Maastricht Ankylosing Spondylitis Enthesitis
Score (MASES)
The number of tender entheses is rated by the MASES.
To assess the MASES, the investigator applies pressure
over 13 different entheses. The patients’ response to firm
palpation over these entheses is noted (0 = absence of
tenderness; 1 = presence of tenderness). The entheseal
sites assessed were the bilateral first costochondral joints,
seventh costochondral joints, posterior superior iliac
spines, anterior superior iliac spines, iliac crests, proximal
insertion of the Achilles tendons, and fifth lumbar spinal
process. The total score ranges from 0 to 13 (22).
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2.1.2.3. Patient Global Assessment of Disease Activity
(PGA)
The PGA is scored from 0 (very well) to 10 (very bad) based
on a VAS. All aspects of disease including activity, function,
and structural damage are evaluated from the patient’s point
of view. The Assessment of Spondyloarthritis International
Society (ASAS) recommends the use of the PGA as an
important component of clinical assessment (22).
2.1.2.4. Ankylosing Spondylitis Disease Activity Score
(ASDAS)
The ASDAS is a composite score of patient-reported
measures and acute-phase reactants that was developed in
order to capture both the subjective and objective aspects
of AS disease activity (23,24). There are four versions of the
ASDAS. We used the ASDAS-ESR and ASDAS-CRP. The
ASDAS has been validated and found to be discriminatory
in assessing disease activity (25).
2.1.3. Assessment of functional level
2.1.3.1. Bath Ankylosing Spondylitis Functional Index
(BASFI)
The BASFI is used for the assessment of physical
functioning in patients with AS. It includes tasks for
which the patients rate their own ability by marking a
vertical line on a 100-mm horizontal line. The ten tasks
comprising the BASFI are as follows: 1) putting on socks,
2) bending forward to pick up a pen, 3) reaching a high
shelf, 4) getting up from an armless chair, 5) getting up
from the floor from lying supine, 6) standing unsupported,
7) climbing steps without a handrail, 8) looking over one’s
shoulders, 9) performing physically demanding activities,
and 10) doing a full day’s activities. The total BASFI score
is calculated by adding all ten scores and dividing by 10.
The Turkish validation of the BASDAI was reported by
Kartepe et al. (26).
2.1.4. Assessment of health-related quality of life
Health status was measured using the 36-Item Short Form
(SF-36) Health Survey, version 2 (SF-36v2), which assesses
eight different aspects of health (27). Item scores can be
aggregated into physical component (PC) summary and
mental component (MC) summary scores. The Turkish
validation of the SF-36 was shown by Koçyiğit et al. (28).
2.2. Statistical analyses
All data were analyzed using the Number Cruncher
Statistical System (2007). Normality of distribution of
variables was analyzed by the Shapiro–Wilk test. Patients
were divided into two groups as Group 1, including patients
with possible or likely NP symptoms (painDETECT score
of ≥13), and Group 2, including patients without NP
symptoms (painDETECT score of <13). Since variables
were distributed nonnormally, differences between the
groups were examined using Mann–Whitney U tests for
continuous variables and chi-square tests (with the Yates

continuity correction as appropriate) for categorical
variables. Continuous variables were presented as
descriptive statistics (median, minimum–maximum) and
categorical variables were recorded as numbers (n) and
percentages (%). Statistical significance was considered at
P < 0.05.
In order to evaluate the correlations between
painDETECT scores and the other parameters, Spearman
correlations were used.
Post hoc power levels of differences that were statistically
meaningful were calculated and these observed differences
had a very high rate of fixation capabilities (99.4%–100%).
The G*Power program was used (Tables 1 and 2).
3. Results
3.1. Patient characteristics
One hundred patients (median age: 37 years, range: 18–71
years; females/males (n): 29/71) fulfilled the criteria and
completed the study. Median disease duration of patients
was 5 years (1–32 years). Percentage of smoking history
and alcohol use was 55% and 16%, respectively. Of the 100
patients, 47% were being treated with sulfasalazine and/
or NSAIDs and 53% were being treated with a biologic
agent alone or combined with sulfasalazine at the time of
the study.
3.2. Pain evaluation
The median low back pain-VAS score was 5 (0–10) and
the median peripheral joint pain-VAS score was 4 (0–10).
The median stiffness VAS score was 2 (0–10). Of the
100 patients, 75% had unlikely NP components, 11%
had possible NP components, and 14% had likely NP
components according to painDETECT scores.
3.3. Disease activity
Most patients had well-controlled disease activity
according to their BASDAI scores. Fifty-four of the 100
patients (54%) were in remission (BASDAI score of <4).
The PGA disease activity median score was 5 (0–10). The
MASES median score was 1 (0–13). The ASDAS-CRP and
ASDAS-ESR median scores were 2.1 and 2.6, respectively.
Twenty-one patients (21%) and 4 patients (14%) were in
remission according to the ASDAS-CRP and ASDAS-ESR,
respectively.
3.4. Functional level and quality of life
The median BASFI score was 2.7 (0–9). The median PC
and MC score of the SF-36 was 36.9 (19.8–61.0) and 44.2
(21.5–57.8), respectively.
3.5. Comparison of groups according to painDETECT
scores
Patients were divided into two groups: Group 1, patients
with possible or likely NP symptoms (painDETECT score
of ≥13), and Group 2, patients without NP symptoms
(painDETECT score of <13). There was no significant
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Table 1. Comparison of pain level, disease activity, functional level, and quality of life between groups.
Group 1 (n = 22)

Group 2 (n = 78)

P

Power

Low back pain-VAS score, median (min–max) / mean ± SD

7.0 (0–10) / 6.6 ± 2.4

4.0 (0–10) / 3.6 ± 2.7

<0.0001

98.6%

Peripheral joint pain-VAS score, median (min–max) / mean ± SD

6.0 (0–10) / 6.1 ± 2.4

2.0 (0–8) / 2.8 ± 2.5

<0.0001

100%

Stiffness-VAS score, median (min–max) / mean ± SD

5.0 (0–10) / 5.3 ± 2.9

2.0 (0–10) / 2.5 ± 2.6

0.003

99.99%

BASDAI score

5.0 (2.2–9)

3.2 (0–10)

<0.0001

99.99%

PGA score

6.0 (0–10)

4.0 (0–10)

0.004

98.5%

MASES score

2.5 (0–11)

1.0 (0–13)

0.055

99.99%

ASDAS-CRP score

2.9 (0.6–4.6)

2.0 (0.6–3.9)

<0.0001

99.99%

ASDAS-ESR score

3.2 (1–4.6)

2.4 (0.6–4.5)

<0.0001

99.99%

BASFI score

5.4 (0–9)

2.05 (0–9.1)

0.001

99.99%

SF-36 PC score

31.9 (19.8–48.7)

41.3 (23.6–61.0)

<0.0001

99.99%

SF-36 MC score

40.7 (21.5–58.4)

44.5 (20.9–57.8)

0.482

Erythrocyte sedimentation rate, mm/h

12.0 (4–82)

9.0 (1–76)

0.381

C-reactive protein, mg/dL

0.4 (0.1–4.4)

0.32 (0.02–1.6)

0.312

Variables are presented as median (min–max) and were analyzed by Mann–Whitney U test.
VAS: Visual analog scale; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; PGA: Patient Global Assessment of Disease Activity; BASFI: Bath
Ankylosing Spondylitis Functional Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; SF-36 PC: SF-36 Short Form Physical Component;
SF-36 MC: SF-36 Short Form Mental Component.

Table 2. Correlation of painDETECT scores with outcome parameters.
painDETECT

Power

r

P

Low back pain-VAS (0–10)

0.477

<0.0001

100%

Morning stiffness-VAS (0–10)

0.413

<0.0001

99.4%

Patient global assessment (0–10)

0.403

<0.0001

99.3%

Peripheral joint-VAS (0–10)

0.406

<0.0001

99.4%

BASDAI

0.589

<0.0001

100%

BASFI

0.509

<0.0001

100%

MASES (0–13)

0.248

0.013

SF-36 MC

0.264

0.015

77%

ESR

0.228

0.022

52.8%

ASDAS-CRP

0.503

<0.0001

100%

ASDAS-ESR

0.523

<0.0001

100%

difference between groups regarding demographic
characteristics (Table 3). Low back pain-VAS scores,
peripheral joint-VAS scores, BASDAI scores, PGA scores,
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ASDAS-CRP and ASDAS-ESR scores, and BASFI scores
were significantly higher in Group 1 compared to those
of Group 2. SF-36 PC scores were significantly lower in
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Table 3. Comparison of demographic properties between groups.
Group 1 (n = 22)

Group 2 (n = 78)

P

Age, median (min–max) / mean ± SD, years

39.5 (27–66) / 41.7 ± 8.9

36.0 (18–71) / 38.4 ± 9.4

0.080

Sex, n (%)

7 females (31%), 15 males (49%)

22 females (29%), 56 males (71%)

0.466

Disease duration, median (min–max) / mean ± SD, years

4.0 (1–30) / 9.5 ± 9.7

6.0 (1–32) / 8.9 ± 7.8

0.776

Education status

Current treatments

n (%)

n (%)

Primary school

10 (10%)

26 (26%)

Junior high school

3 (3%)

8 (8%)

High school

4 (4%)

21 (21%)

University

5 (5%)

22 (22%)

n (%)

n (%)

NSAIDs

5 (5%)

20 (20%)

NSAIDs and sulfasalazine

5 (5%)

18 (18%)

Sulfasalazine

1 (1%)

0 (0%)

Biologic agent

8 (8%)

33 (33%)

Biologic agent and
sulfasalazine

3 (3%)

7 (7%)

0.759

0.389

Smoking

15 (68.2%)

40 (51.3%)

0.404

Alcohol use

4 (18.1%)

14 (17.9%)

0.599

Continuous variables are presented as median (min–max) and categorical data are presented as n (%). Categorical data were analyzed using the chisquare test (χ2) and continuous variables were analyzed by the Mann–Whitney U test.

Group 1 compared to Group 2. There was no significant
difference between groups regarding SF-36 MC scores,
ESR values, CRP levels, and MASES scores (Table 1).
3.6. Correlation of painDETECT scores and other
parameters
Total painDETECT scores correlated moderately with
BASDAI scores (r < 0.589, P < 0.0001), low back pain-VAS
scores (r = 0.477, P < 0.0001), peripheral joint-VAS scores
(r = 0.406, P < 0.0001), morning stiffness-VAS scores (r
= 0.413, P < 0.0001), PGA scores (r = 0.403, P < 0.0001),
ASDAS-CRP scores (r = 0.503, P < 0.0001), ASDAS-ESR
scores (r = 0.523, P < 0.0001), and BASFI scores (r = 0.509,
P < 0.0001). A weak correlation between painDETECT
scores and MASES scores (r = 0.248, P = 0.013) and ESR
values (r = 0.228, P = 0.022), along with a weak inverse
correlation with SF-36 PC scores (r = –0.264, P = 0.015),
were also observed (Table 2).
4. Discussion
In this study, we found that 25% of patients with AS
probably have NP as determined by the painDETECT
questionnaire. Patients with NP symptoms have higher
VAS scores for low back pain, peripheral joint pain,

morning stiffness, and PGA, along with higher BASDAI
scores and lower BASFI and SF-36 scores, as compared to
patients without NP symptoms.
There may be a neuropathic component that affects
pain perception in AS. It was proposed by Pollard et al.
that arthritic joints expand their total receptive field to
the surrounding noninflamed tissue, called peripheral
sensitization (29). Another peripheral mechanism in the
development of neuropathic pain in AS patients could
be the focal demyelination of nonnociceptive, large
myelinated fibers in those patients (30).
Inflammatory radiculopathy without any mechanic
compression advanced by local inflammation of the axial
spine in AS may be another peripheral mechanism (31).
Dysregulation of central pain processing mechanisms and
central sensitization is the underlying pathology of NP.
Wu et al. (12) showed that higher painDETECT scores in
AS patients were found to be correlated with thinning of
the primary somatosensory cortex and thickening of the
primary motor cortex. The study of Wu et al. is valuable
since it showed objective findings of central sensitization,
which supports the reliability of painDETECT in assessing
neuropathic pain.

261

GELER-KÜLCÜ et al. / Turk J Med Sci
Wu et al. also demonstrated that back pain includes
a NP component in more than half of patients with
AS (12). In our study, we found this rate to be 25%. We
investigated 100 AS patients and the associations between
painDETECT scores and clinical parameters. However,
Wu et al. included only 17 patients in their study. The
reason for this higher ratio may be the smaller sample
size. However, the aim of Wu et al. was to investigate the
correlation between painDETECT scores and the sensory
thresholds measured by a standardized set of von Frey
filaments and a computer-controlled Peltier device (TSAII NeuroSensory Analyzer, Medoc) and the functional
MRI findings, and their sample size was adequate for such
a study.
Despite almost 60% of patients being in remission
according to BASDAI scores, 65% still reported clinically
significant low back pain and 53% peripheral pain.
According to the painDETECT questionnaire, 14% of all
patients had likely NP, while 11% had possible NP features.
These patients were shown to have more severe pain,
lower functional level and quality of life, and higher
disease activity. Clinically significant pain was defined
as an average pain score of ≥4. This threshold was based
on several previous studies that identified pain intensity
levels of ≥4 out of 10 as moderate to severe or unacceptable
(32,33).
In our study, patients receiving treatment for at least
for 3 months were included in order to exclude untreated
patients. This suggests that other pain mechanisms
together with inflammation may play a role since pain
control remains inadequate although patients are in
remission (34).
There are some recent studies that evaluated NP in
rheumatic diseases. Koop et al. (11) found similar results
in patients with rheumatoid arthritis. They found 17%
likely and 24% probable NP in their survey. Similar to
our results, they found high VAS scores (>4), although
the majority of the patients were in remission according
to the DAS-28. In another study by Meirinhos et al. (35),
19% of rheumatoid arthritis patients having likely NP
prevalence was reported. Contrary to these results, Ahmed
et al. (10) showed that a large proportion of subjects with
rheumatoid arthritis demonstrated likely or probable
NP features based on painDETECT scores. However,
the proportion of AS patients with likely NP was lower
than that reported by Wu et al. (12). NP symptoms have
been reported much more in patients with osteoarthritis
(8,9,36) and fibromyalgia (6,7). Further studies should be
designed to evaluate NP frequency in AS patients with
larger sample sizes.
No previous studies examined correlations of NP
symptoms with disease activity, functional level, and
quality of life in patients with AS. In the current study,
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NP symptoms were not related to any of the demographic
features. However, painDETECT scores were correlated
with BASDAI scores, PGA scores, BASFI scores, and the
PC of SF-36 scores. A similar relationship was shown in
rheumatoid arthritis patients by Koop et al. (11). Ahmad
et al. (10) found that people with rheumatoid arthritis
prescribed a combination of biologics and DMARDs had
an overall high mean VAS score compared with other
groups, despite DAS-28 scores suggesting good control
of disease activity. In our study, we did not evaluate the
subgroups according to current medications. However,
scores for the VAS, BASDAI, BASFI, PC of SF-36, and
other parameters did not differ between patients with NP
and patients without NP. On the other hand, we showed
that although 60% of patients were in remission according
to the BASDAI, 65% of the patients had high VAS scores.
The results of our study and those of Ahmad et al. suggest
that disease activity measures may be affected by NP rather
than by inflammation alone (10).
The BASDAI is the most widely used activity indicator
in both routine clinical practice and drug trials in which
the efficacy of novel drugs are tested (14,37). However,
the BASDAI is a self-reported questionnaire and does not
include any objective parameters. It may be influenced by
other diseases. Potential factors that may influence these
scores should also be taken into account, such as NP, other
coexisting musculoskeletal disorders such as fibromyalgia,
and depression (38). Otherwise, overtreatment or
inadequate treatment could be an outcome in some AS
patients since treatment strategies are planned according
to BASDAI scores. We also utilized the ASDAS since it is
a more objective disease activity assessment tool because
it includes CRP and/or ESR values in addition to patientreported assessments. Some researchers have concluded
that the ASDAS-CRP and ASDAS-ESR discriminate high
and low disease activity better than the BASDAI or acutephase reactants (39,40). However, we found similar results
from the ASDAS and BASDAI. The reason for this result
may be the normal ranges of ESR and CRP values of the
patients who received at least 3 months of therapy before
the study. We thus concluded that the reason for this
difference was not inflammation.
Medications are expensive and can have serious side
effects. Although drugs targeting inflammation are known
to have no effect on NP mechanisms, one study by Wu et
al. (41) showed that after tumor necrosis factor inhibitor
(TNFi) treatment, AS patients had partially reversed
hyposensitivity in thermal and mechanical detection,
compared with healthy subjects, of the foot. They showed
that TNFi attenuates the NP component of AS in addition
to reversing sensory loss and improving lateral spinal
mobility. However, in our study, there were no differences
in terms of medications between AS patients with NP and
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patients without NP. Despite the findings of Wu et al., we
recommend that treatment decisions and alterations be
made after the treatment of accompanying NP.
Our study has several strengths. First, it showed the
correlation between the painDETECT questionnaire and
clinical data, BASDAI and BASFI scores, and quality
of life. This gives insight into the origin of pain in AS
patients, and also the effect of NP on the daily life (42).
Another strength of our study was excluding patients with
comorbidities, including obesity, fibromyalgia, diabetes
mellitus, smoking, and secondary osteoarthritis, which
might exacerbate pain in AS (43). Recent studies have
shown that the majority of AS patients have accompanying
fibromyalgia (44–46), often considered the prototypical
central pain syndrome (47). Based on this knowledge, we
evaluated our patients with the 2010 American College
of Rheumatology fibromyalgia criteria and excluded the
patients with fibromyalgia.
Depression and anxiety also contribute to BASDAI
scores. Although we excluded patients who had known
depression or mood disorders and were receiving
antidepressants, we did not evaluate the patients with a

screening tool for depression or anxiety. This may be a
potential limitation of our study. There are some other
limitations of this study. The number of patients was
relatively small, with 100 participants recruited. NP in
patients with AS should be further studied with larger
sample sizes. The patients included in this study were
recruited from normal daily clinical practice and were
receiving at least 3 months of therapy, and therefore
closely resembled current ‘well-controlled’ AS patients.
The findings, however, may not be applicable to all AS
populations. Additionally, the cross-sectional nature of this
study does not allow any determination of the direction of
associations between NP symptoms and clinical variables.
In conclusion, mixed pain patterns may be seen in
some patients with AS. This condition is related to high
disease activity and poor functional level and quality
of life. Clinicians could evaluate people with AS using
painDETECT in order not to underestimate NP. If
clinicians find evidence of likely NP, they should treat the
patient with drugs targeting NP. Disease activity should
be reevaluated after NP treatment in order to avoid
overtreatment of patients with AS.
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